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Abstract
Background: The treatment of Irritable bowel syndrome (IBS) is still challenging. Partially hydrolyzed guar gum (PHGG)
is a known prebiotic fiber. To assess the effects of PHGG on clinical symptoms of IBS patients in a prospective randomized
double blind placebo-controlled study.
Methods: Suitable IBS patients were recruited into an 18-week-long study (2 weeks of run-in, 12 weeks of treatment and
4 weeks of follow-up). They were blindly randomized to receive 6 gr of PHGG or placebo. Treatment efficacy was
evaluated by the Francis Severity IBS score, the IBS quality-of-life scores and scored parameters of weekly journal
of symptoms. Deltas of changes between the final and baseline scores were compared between two groups.
Results: Of 121 patients who underwent randomization, 108 patients (49 in the PHGG group and 59 in the
placebo group) had all the data needed for intention-to-treat analysis. A 12-week administration of PHGG led to a
significant improvement of journal bloating score in the PHGG group versus placebo (−4.1±13.4 versus −1.2±11.9,
P=0.03), as well as in bloating+gasses score (−4.3±10.4 versus −1.12±10.5, P = 0.035). The effect lasted for at least
4 weeks after the last PHGG administration. PHGG had no effect on other journal reported IBS symptoms or on
Severity and Quality of life scores. There were no significant side effects associated with PHGG ingestion. The rate
of dropouts was significantly higher among patients in the placebo group compared with the PHGG group
(49.15% versus 22.45%, respectively, P = 0.01).
Conclusions: The results of this study support the administration of 6 g/day PHGG for IBS patients with bloating.
Trial registration: NCT01779765
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Background
Irritable bowel syndrome (IBS) is a functional gastrointes-
tinal disorder [1]. It is a benign, relapsing chronic disorder
characterized by recurrent abdominal pain, bloating and
altered bowel function. IBS has an enormous impact on
the quality of life (QOL) of the patients by causing a sig-
nificant disability and absence from work and school [2].
Treatment of IBS is very problematic. Despite a wide range
of pharmacological and non–pharmacological therapies,
there is no universally accepted therapeutic approach [3].
The etiology and underlying pathogenesis of IBS is com-
plex and not fully understood [4]. One of the factors that
contribute to IBS is abnormality in the gut flora [4]. The
gut microbiota is influenced by a diverse range of factors,
including diet, fiber content in food, antibiotic usage, in-
fection, stress, and probiotic and prebiotic use [5–7].
Guar gum is a water-soluble polysaccharide found in
the seeds of guar, a plant indigenous to India and Pakistan.
The main component of guar gum is galactomannan. It
has been used in food processing as a thickener and emul-
sion stabilizer. Because guar gum is extremely viscous, it
is very difficult to incorporate it in food in quantities large
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enough to obtain a physiological effect. The proposed so-
lution was partial hydrolyzation of guar gum. Partially hy-
drolyzed guar gum (PHGG) has some attractive physical
and chemical properties. It is completely water soluble, in-
visible in solution, taste-free, stable at a low pH, heat toler-
ant and is known as a prebiotic fiber. Prebiotics are
defined as non-digestible food ingredients that beneficially
affect the host by selectively stimulating the growth and/
or the activity of one bacterium or a limited number of
bacteria in the colon that can improve host health. PHGG
increases the concentration of bifidobacterium and lacto-
bacilli species and increases short-chain fatty acids in the
colonic lumen [8–13]. It has also been shown to have a
positive effect on some medical conditions, e.g., redu-
cing blood cholesterol and controlling blood sugar
levels [14–16]. In addition, it was found to be effective in
the treatment of acute diarrhea in children and adult pa-
tients of intensive care units [17–19]. PHGG has proved
to be effective in softening and improving fecal output
and increasing bulking capacities (fecal weight, frequency
of defecation, and fecal excretory feeling) [10, 11, 20, 21]
It has also been investigated as a possible treatment for
IBS and found to have a positive effect, especially in
constipation-predominant IBS [22–26].
Previous studies on the use of PHGG in patients with
IBS, however, were biased by methodological problems
(lack of placebo group and double blind randomization,
small groups, short duration of study) [5, 6]. We
assessed the short- and long–term effects of PHGG ad-
ministration on clinical symptoms of IBS patients.
Methods
This prospective randomized double blind placebo-
controlled study was performed in the Clinical Nutrition
Unit of Tel-Aviv Sourasky Medical Center (TASMC) in
collaboration with the Departments of Gastroenterology
in TASMC and in Sapir Medical Center, Israel. The study
protocol was approved by the TASMC Helsinki committee
(Number TLV-0242-12) and was registered in the NIH
(NCT01779765). The patients were recruited from the
medical centers’ outpatient clinics. They were screened
according to the study inclusion criteria and their willing-
ness to participate. All recruited patients provided in-
formed consent. The inclusion criteria were as follows:
(1) fulfillment of the Rome III criteria for IBS, (2) availabil-
ity of at least one gastrointestinal (GI) imaging study
during the last five years (colonoscopy, sigmoidoscopy, ab-
dominal ultrasonography, barium enema) for patients
older than 50 years, (3) age 18–77 years at the time of
screening, (4) provision of written informed consent, and
(5) commitment of availability throughout the 18-week
study period. The exclusion criteria were: (1) major ab-
dominal surgery in the past, (2) the presence of any active
(organic) GI disease, (3) past or present major medical or
psychiatric illness, (4) alarming symptoms (rectal bleeding,
weight loss, etc.), (5) pregnancy, (6) family history of colo-
rectal carcinoma at age younger than 50 years or a family
history of IBD, (7) abnormal laboratory studies (blood bio-
chemistry, liver enzymes, complete blood count, abnormal
thyroid function, celiac serology), (8) non-adjusted diet in
the case of lactose intolerance, (9) recent travel to regions
with endemic parasitic diseases, (10) probiotics or prebi-
otics administration two weeks prior to entry into the trial
and (11) antibiotic use at least 3 months prior to entry
into the trial.
All types of IBS were included in the study. Based on their
dominant complaint, the patients were classified as
constipation-predominant, diarrhea-predominant and mixed
types. According to Rome III criteria, IBS with constipa-
tion was defined as: hard or lumpy stools ≥25% and loose
(mushy) or watery stools <25% of bowel movements, IBS
with diarrhea— as loose (mushy) or watery stools ≥25%
and hard or lumpy stool <25% of bowel movements,
Mixed IBS– as hard or lumpy stools ≥ 25% and loose
(mushy) or watery stools ≥25% of bowel movements.
The overall length of the study was 18 weeks (two weeks
for the run-in period, 12 weeks of treatment and four
weeks of follow-up) and was conducted between January
2013 and December 2014 (recruitment & follow up). The
randomization list was made by the medical center's clin-
ical trials pharmacy, using a block randomization of vary-
ing block size. The pharmacy staff were not involved in
the conduct of the study. All of the clinical nutrition unit
staff & participants were blinded during the whole trial.
Patients were randomly assigned to one of two groups
and received either PHGG (Sunfiber produced by Taiyo
Kagaku Co., Ltd., Japan) in a dosage of three g/day for the
first seven days and then six g/day for 11 weeks or placebo
(Maltodextrin) in a dosage of three g/day for the first
seven days and then six g/day for 11 weeks. Maltodextrin
is a polysaccharide that is used as a food additive. It is pro-
duced from starch by partial hydrolysis and is usually
found in the form of a white hygroscopic spray-dried pow-
der. The patients were instructed to dissolve the sachet
that contained either 6 g PHGG or placebo in a glass of
water and to drink one glassful per day. Each patient was
identified by a serial number, and the entire cohort under-
went double blind randomization into the two groups (the
study product and the placebo). They were asked not to
not to take any probiotics or prebiotics during the study
and to continue eating their usual diet and to take their
usual medications.
A total of six visits were scheduled over the 18 weeks:
the first visit at two weeks before the administration of the
study product/placebo, three monthly visits during the in-
gestion of the study product/placebo and a follow-up visit
at one month since the last ingestion of the study prod-
uct/placebo. Demographic data were collected, a medical
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history was taken, inclusion/exclusion criteria were
checked, informed consent was signed and the random-
ization took place at the first visit. The clinical severity of
the IBS symptoms was evaluated by the Francis Severity
IBS score and by the IBS quality-of-life (QOL) scores at
each visit [27, 28]. In addition, the patients filled out a
self-reporting daily journal of the severity of symptoms.
Adverse events and compliance were monitored through-
out the study period.
The Francis Severity IBS score contains five questions,
each given a value from 0 (no symptoms) to 100 (most se-
vere) for measuring the severity and frequency of IBS-
associated symptoms. The total Francis Severity IBS score
is a sum of all the above and ranges from 0 to 500. The
QOL questionnaire consists of 34 questions, each rated
from 1 (mild) to 5 (severe), and their sum yields the total
QOL score, ranging from 0 to 170. This questionnaire was
validated for the Hebrew language [29, 30]. The self-
reporting daily journal was filled out for one week (each
time at one week before the visit) and it consisted of sev-
eral questions on abdominal pain, bloating, gasses and
number of bowel movements per 24 h, and the score
ranged from 0 to 70 for every question.
Statistical analysis
The intention-to-treat analysis was performed on all pa-
tients who underwent randomization. An additional ana-
lysis included only those subjects who completed 12
weeks of study product/placebo administration. The pri-
mary endpoints were changes (delta) in the scores of
journal parameters, the Francis Severity score, and the
total QOL scores between the values at the end of treat-
ment versus baseline and between the end of the follow-
up period versus the baseline values. Comparisons of
demographic and clinical variables as well as baseline sever-
ity and QOL scores between treatment and placebo groups
were performed using Fisher’s exact test and the Mann–
Whitney non-parametric test, as applicable. Changes in
values of all scores were examined using the mixed model
for analysis of variance (ANOVA with repeated measures).
This model allows the evaluations of the effect of each
factor on the outcome as well as the interactions be-
tween the factors. The mixed model used group (treat-
ment versus placebo) and time as factors. A P value of
0.05 was taken as significant.
Results
One-hundred and eighty-six patients underwent screening
for this study. Of them, 121 patients fulfilled the inclusion
criteria, signed informed consent and underwent a blind
randomization into either the 6 g PHGG group or the pla-
cebo group. During the two-week run-in-period, 13 pa-
tients dropped out of the study (two patients due to travel
plans, eight withdrew consent, and three were unwilling
to stop probiotics). The remaining 108 patients attended
the second visit of the study, provided baseline IBS param-
eters and started the administration of the study product/
placebo. All these 108 patients were included in the
intention-to-treat analysis. Table 1 presents the demo-
graphic data of these patients and their IBS baseline pa-
rameters. The PHGG group including 49 patients and the
placebo group included 59 patients. The patients in both
groups were of similar age (46.2±19.2 and 40.8±15.6 years
for the PHGG and placebo groups, respectively, P = 0.1).
IBS was longstanding for most of the participants, with a
mean duration of 15.2±14.9 years in the study group and
13.4±12.4 years in the placebo group, P = 0.5. The gender
distribution was similar in both groups (female predomin-
ant). Most of the patients in both groups had a mixed type
of IBS (24/49 patients in the study group and 40/59 pa-
tients in the placebo group). Table 1 demonstrates the se-
verity of IBS symptoms at baseline. The PHGG group had
a more severe degree of IBS than the placebo group in
terms of abdominal pain (31±15.6 versus 21.6±16.4),
gasses (38.3±15.2 versus 32.5±13.5) and total severity
score (307±85 versus 267.9±115.7) (P = 0.003, P = 0.036
and P = 0.046, respectively). Of course, the design of pro-
spective randomized double-blind placebo controlled
study could not allow us to predict this kind of distribu-
tion of patients. To overcome this, the dynamic changes
in all the scores during the study were calculated as a dif-
ference from the baseline and not as an absolute value.
The patients took the study product/placebo for 12
weeks. They were then instructed to stop the administra-
tion of the products and entered four weeks of follow-up.
A total of 92 patients completed one month of treatment,
78 patients completed two months, 68 patients completed
three months and 41 patients completed three months of
treatment and one month of follow-up. The rate of drop-
outs was significantly higher among patients in the placebo
group (29 patients) compared to the PHGG group (11 pa-
tients) (49.15% versus 22.45%, respectively, P = 0.01). Dur-
ing the study, nine PHGG patients and nine placebo
patients reported experiencing mild side effects, such as
abdominal pain, gasses, diarrhea, heartburn, nausea. It was
impossible to conclude if these side effects were related to
PHGG because of their similarity to IBS symptoms. The
side effects were mild and discontinued immediately after
the stop of PHGG/placebo.
Table 2 presents the results of the effect of PHGG/pla-
cebo on IBS symptoms in our study over the 12 weeks
of treatment, and Fig. 1 demonstrates the same results
graphically. The assessment was performed based on
intention-to-treat analysis. Delta between the change
and the baseline for all the scores was chosen to be eval-
uated and not the absolute values of scores because the
PHGG group appeared to have more severe IBS disease
compared to the placebo group. The results of the study
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clearly demonstrated that the PHGG group had a signifi-
cant improvement in bloating score (−4.1±13.4 versus
−1.2±11.9) and bloating+gasses scores (−4.3±10.4 versus
−1.12±10.5) compared to the placebo group (P = 0.03
and P = 0.035, respectively). This effect was consistent
throughout the 12-week study period, as is apparent
from the P values of interaction between the time and
groups (P = 0.027 and P = 0.03 for bloating and bloating
+gasses scores, respectively). After four weeks since the ces-
sation of PHGG ingestion, the bloating and gasses scores
started to arise again, although the difference was not sig-
nificant (P = 0.9 and P = 0.83, respectively), indicating that
Table 1 Baseline parameters of the participants
Groups PHGG group Placebo group P value
Number 49 59
Age (years) 46.2 ± 19.2 40.8 ± 15.6 1.0
Gender (male/female) 15/34 22/37





Time from diagnosis (years) 6.2 ± 7.1 5.2 ±6.7 0.47
Journal Bloating score 32.8 ± 19.1 30.6 ± 17.6 0.6
Journal Abdominal pain score 31 ± 15.6 21.6 ± 16.4 0.003
Journal Gasses score 38.3 ± 15.2 32.5 ± 13.5 0.036
Number of bowel movements/week 13.4 ± 11 13.7 ± 9.6 0.9
Severity score 307 ± 85 267.9 ± 115.7 0.046
Quality of life score 88.8 ± 27.2 83.4 ± 26.3 0.3
Values are given in mean ± standard deviation
Table 2 Changes in study parameters over 3 months




(1st month baseline) (2nd month baseline) (3rd month baseline)
Bloating score 0.027 0.03
PHGG -3.1 ± 10.9 -7 ± 12.9 -4.1 ± 13.4
Placebo -0.07±9.9 0.3±11 -1.2±11.9
Abdominal pain score 0.357 0.334
PHGG -3.7±11.3 -5.5±14.2 -3.4±11.9
Placebo -1.4±10.4 -2.7±9.5 -2.8±10.8
Bloating + gasses score 0.03 0.035
PHGG -4.2±10.3 -7.1±10.6 -4.3±10.4
Placebo -0.08±6.9 0.3±10.1 -1.12±10.5
Number of bowel movements/week 0.97 0.713
PHGG -1±5.4 -0.6±4.6 -0.8±5.1
Placebo -0.6±4.9 -0.4±4.8 -0.4±4.1
Severity score 0.441 0.421
PHGG -41.9±88.5 -67.9±98.8 -64.8±102.3
Placebo -35.6±74.0 -47.3±76.0 -53.9±86.7
Quality of life score 0.643 0.788
PHGG -4.7±13.6 -7.8±17.6 -7.8±20.7
Placebo -6.0±11.8 -7.4±12.8 -7.4±12.8
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the positive effect of PHGG did not diminish after four
weeks of follow-up. Additionally, Table 2 demonstrates that
PHGG had no advantage over the placebo regarding other
IBS symptoms, such as abdominal pain (−3.4±11.9 versus
−2.8±10.8), stool frequency (−0.8±5.1 versus −0.4±4.1), total
severity score (−64.8±102.3 versus −53.9±86.7) and
QOL (−7.8±20.7 versus −9.1±14.3) (P = 0.334, P = 0.713,
P = 0.421, and P = 0.788, respectively). The net placebo ef-
fect resulted in a 20.1% improvement in the total severity
score for the patients in the placebo group.
Because the score of stool frequency has different
meanings in patients with diarrhea-predominant and
constipation-predominant IBS, the analysis of this score
was performed separately for the patients with these two
disease types. PHGG intake did not decrease the stool
frequency in diarrhea-predominant patients nor did it
increase stool frequency in constipation-predominant
patients compared to the placebo group. However, a
proper statistical evaluation could not been performed
because of the relatively small number of patients in the
groups with these types of IBS.
Discussion
This prospective, randomized, double blind placebo-
controlled study on the effects of 12 weeks of adminis-
tration of 6 g/day PHGG on the clinical symptoms of
IBS patients revealed that PHGG produced a significant
improvement on bloating and gasses symptoms of IBS
patients compared to placebo. Its use was not associated
with any significant side effects. The effect of this pre-
biotic lasted at least four weeks after the cessation of its
ingestion. PHGG did not, however, have any effect on
abdominal pain, stool frequency, or QOL. Therefore, the
Fig. 1 Dynamic changes in IBS parameters over 3 months of treatment expressed as delta from the baseline values
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results of this study support the administration of 6 g/
day PHGG for IBS patients with bloating and gasses.
The administration of PHGG in IBS patients has been
reported by others. Giaccari et al [24] administered PHGG
to 134 IBS patients in addition to a balanced diet and
found a positive effect of PHGG on various IBS symp-
toms. Their study, however, was observational and not
randomized, there was no placebo group, and PHGG was
taken as a supplementation to a balanced diet. Paresi et al
[22] treated 188 IBS patients with a high–fiber diet sup-
plementation (30 g/day of wheat bran) or PHGG (5 g/day)
for 12 weeks. Improvements in core IBS symptoms were
observed with both the bran and PHGG, but the latter
was better tolerated and preferred by patients. That cross-
over study was very interesting, but the lack of a placebo
group and a follow-up period posed important limitations.
The same authors [23] published an important paper in
which they compared the effects of PHGG administered
at two dosages (5 and 10 g/day) for 3 months in patients
with IBS, followed by three months of follow-up. The
symptoms of IBS and QOL improved significantly for
the patients in both dosage groups. However, this posi-
tive effect was significantly reduced during the three-
month follow-up.
This study’s major strength lies in its being the first pro-
spective, randomized, double blind placebo-controlled in-
vestigation of the effect of PHGG in the setting of IBS. The
profound placebo effect on IBS symptoms (ranging from
20-50%) is well-established [5, 6]. In the current study, the
net placebo effect was about 20%. In fact, every significant
study regarding IBS should be placebo-controlled. There-
fore a proven statistically significant effect on bloating and
gasses over placebo in our study has an important signifi-
cance. One weakness of the current study is the relatively
high dropout rate, although most of the dropouts were
in the placebo group (47.5%) compared with the PHGG
group (23.5%), supporting a positive effect of PHGG.
The follow-up period in our study was four weeks,
which is adequate, but a longer period would be able to
establish whether PHGG treatment should be episodic
or continuous.
This study did not focused on the mechanism of PHGG
influence on the GI tract of IBS patients. Previous studies
proved an ability of PHGG to act as a prebiotic fiber and
influence the microbiota. For example, in two clinical stud-
ies (one –in constipated women and the second one in
healthy volunteers) several weeks of PHGG administration
resulted in the increase of Bifidobacterium and Lactobacil-
lus spp and the decrease of Clostridium spp, Enterobacte-
riaceae and Streprococcaceae [9, 11]. Moreover, in vitro
fermentation of PHGG results in an active production of
short chain fatty acids, which are important for colon
health as a primary energy source of colonocytes [31].
Therefore, presumably the mechanisms of PHGG impact
on the GI tract of IBS patients are through a microbiota
change and a positive stimulating effect on colonocytes.
However, the exact mechanism of PHGG influence is still
unknown and should be a subject of further research.
Conclusion
This prospective, randomized, double blind placebo-
controlled study supports the administration of 6 g/day
PHGG for IBS patients with an expected clinical effect
on bloating and gasses. It demonstrates that prebiotic
administration has a significant effect on the symptoms
of such challenging clinical condition as IBS. This find-
ing emphasizes the significance of gut microbiota in
pathogenesis and treatment of IBS.
Abbreviations
IBS: Irritable bowel syndrome; PHGG: Partially hydrolyzed guar gum;
QOL: Quality of life; GI: Gastrointestinal; IBD: Inflammatory Bowel Syndrome.
Competing interests
The authors declare that they have no competing interests.
Author contributions
Conception and design of the study (NV), acquisition of data (EN, AH, ET, HY,
HS, TN), analysis and interpretation of the data (EN, NV), drafting the article
(EN), final approval (EN, NV). All authors approved the final version of the
article: EN, AH, ET, HY, HS, TN & NV).
Author information
Guarantor of article: Prof. Nachum Vaisman
Acknowledgments
Declaration of funding interests: Pro Natura company, Bad Vilbel, Germany;
Sunwic AB company, Kungsbacka, Sweden were funders but the design and
performance of the study were done independently by the Unit of Clinical
Nutrition, TASMC, Israel.
Editing: Esther Eshkol, the institutional medical copyeditor, is thanked for
editorial assistance.
Author details
1Unit of Clinical Nutrition, Tel-Aviv Sourasky Medical Center, Sackler School of
Medicine, Tel-Aviv University, Tel-Aviv 6423906, Israel. 2The Department of
Gastroenterology, Tel-Aviv Sourasky Medical Center, Sackler School of
Medicine, Tel-Aviv University, Tel-Aviv, Israel. 3The Department of
Gastroenterology, Sapir Medical Center, Kfar-Saba, Israel.
Received: 14 November 2015 Accepted: 27 January 2016
References
1. Olden K. Diagnosis of irritable bowel syndrome. Gastroenterology. 2002;122:
1701–14.
2. Longstreth GF, Wilson A, Knight K, Wong J, Chiou CF, Barghout V, et al.
Irritable bowel syndrome, health care use, and costs: a U.S. managed care
perspective. Am J Gastroenterol. 2003;98:600–7.
3. Akehurst R, Kaltenhaler E. Treatment of irritable bowel syndrome: a review
of randomised controlled trials. Gut. 2001;48:272–82.
4. Barbara G, De Giorgio R, Stanghellini V, Cremon C, Salvioli B, Corinaldesi R.
New pathophysiological mechanisms in irritable bowel syndrome. Aliment
Pharmacol Ther. 2004;20 Suppl 2:1–9.
5. Saggioro A. Probiotics in the treatment of irritable bowel syndrome. J Clin
Gastroenterol. 2004;38 Suppl 6:S104–6.
6. Niv E, Naftali T, Hallak R, Vaisman N. The efficacy of Lactobacillus reuteri ATCC
55730 in the treatment of patients with irritable bowel syndrome—a double
blind, placebo-controlled, randomized study. Clin Nutr. 2005;24:925–31.
7. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic
microflora—introducing the concept of prebiotics. J Nutr. 1995;125:1401–12.
Niv et al. Nutrition & Metabolism  (2016) 13:10 Page 6 of 7
8. Tuohy KM, Kolida S, Lustenberger AM, Gibson GR. The prebiotic effects of
biscuits containing partially hydrolysed guar gum and fructo-
oligosaccharides—a human volunteer study. Br J Nutr. 2001;86:341–8.
9. Okubo T, Ishihara N, Takahashi H, Ishihara N, Yamanaka J, Yamamoto T, et al.
Effects of partially hydrolyzed guar gum intake on human intestinal
microflora and its metabolism. Biosci Biotechnol Biochem. 1994;58:1364–9.
10. Takahashi H, Yang SI, Hayashi CH, Kim M, Yamanaka J, Yamamoto T.
Effect of partially hydrolysed guar gum on fecal output in human volunteers.
Nutr Res. 1993;13:649–57.
11. Takahashi H, Wako N, Okubo T, Ishihara N, Yamanaka J, Yamamoto T.
Influence of partially hydrolysed guar gum on constipation in women.
J Nutr Sci Vitaminol. 1994;40:251–9.
12. Weaver GA, Tangel C, Krause JA, Alpern HD, Jenkins PL, Parfitt MM, et al.
Dietary guar gum alters colonic microbial fermentation in azoxymethane-
treated rats. J Nutr. 1996;126:1979–81.
13. Phillips SF. Physiology and pathophysiology of the colon: relationship to
constipation. In: Barbara L, Corinaldesi R, Gizzi G, Stanghellini V, editors.
Chronic constipation. London: WB Saunders; 1996. p. 19–37.
14. Jenkins DJ, Leeds AR, Slavin B, Mann J, Jepson EM. Dietary fiber and blood
lipids: reduction of serum cholesterol in type 2 hyperlipidemia by guar
gum. Am J Clin Nutr. 1979;32:16–8.
15. Jenkins DJ, Goff DV, Leeds AR, Alberti KG, Wolever TM, Gassull MA, et al.
Unabsorable carbohydrates and diabetes: decreased post–prandial
hyperglycemia. Lancet. 1976;2:172–4.
16. Yamatoya K, Sekiya K, Yamada H. Effects of partially hydrolyzed guar gum
on postprandial plasma glucose and lipids levels in humans. J Jpn Soc Nutr
Food Sci. 1993;46:199–203.
17. Alam NH, Meier R, Schneides H, Sarker SA, Bardhan PK, Mahalanabis D, et al.
Partially hydrolysed guar gum-supplemented oral rehydration solution in
the treatment of acute diarrhoea in children. J Pediatr Gastroenterol Nutr.
2000;31:503–7.
18. Homman HH, Kemen M, Fuessenich C, Senkal M, Zumtobel V. Reduction in
diarrhea incidence by soluble fiber in patients receiving total or
supplemental enteral nutrition. J Parenter Enteral Nutr. 1994;18:486–90.
19. Rushdi TA, Pichard C, Khater YH. Control of diarrhea by fiber-enriched diet
in ICU patients on enteral nutrition: a prospective randomized controlled
trial. Clin Nutr. 2004;23:1344–52.
20. Yamatoya K, Kuwano K, Suzuki J, Mitamura T, Sekeiya K. Effect of hydrolyzed
guar gum on frequency and feeling of defecation in humans. J Appl
Glycosci. 1995;42:251–7.
21. Patrick PG, Gohman SM, Marx SC, DeLegge MH, Greenberg NA. Effect of
supplements of partially hydrolyzed guar gum on the occurrence of
constipation and use of laxative agents. J Am Diet Assoc. 1998;98:912–4.
22. Parisi GC, Zilli M, Miani MP, Carrara M, Bottona E, Verdianelli G, et al. High-
fiber diet supplementation in patients with irritable bowelsyndrome (IBS).
Comparison between wheat bran diet and partially hydrolyzed guar gum
(PHGG). Dig Dis Sci. 2002;47:1697–704.
23. Parisi G, Bottona E, Carrara M, Cardin F, Faedo A, Goldin D, et al. Treatment
effects of partially hydrolyzed guar gum (PHGG) on symptoms and quality
of life of patients with irritable bowel syndrome (IBS). A multicenter,
randomized open trial. Dig Dis Sci. 2005;50:1107–12.
24. Giaccari S, Grasso G, Tronci S, Allegretta L, Sponziello G, Montefusco A et al.
Gomma guar parzialmente idrolizzata: una fibra come coadiuvante nella
sindrome del colon irritabile. Clin Ter. 2001;152:21–5.
25. Giannini EG, Mansi C, Dulbecco P, Savarino V. Role of partially hydrolyzed
guar gum in the treatment of irritable bowel syndrome. Nutrition.
2006;22:334–42.
26. Russo L, Andreozzi P, Zito FP, Vozzella L, Savino IG, Sarnelli G, et al. Partially
hydrolyzed guar gum in the treatment of irritable bowel syndrome with
constipation: effects of gender, age, and body mass index. Saudi J
Gastroenterol. 2015;21(2):104–10.
27. Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring
system: a simple method of monitoring irritable bowel syndrome and its
progress. Aliment Pharmacol Ther. 1997;11:395–402.
28. Drossman DA, Patrick DL, Whitehead WE, et al. Further validation of the IBS-
QQL: a disease–specific quality–of-life questionnaire. Am J Gastroenterol.
2000;95:999–1007.
29. Sperber AD, DeVellis RF, Boehlecke B. Cross-cultural translation:
methodology and validation. J Cross-Cult Psychol. 1994;25:501–24.
30. Sperber AD. Translation and validation of study instruments for cross-
cultural research. Gastroenterology. 2004;126:S124–8.
31. Pylkas AM, Juneja LR, Slavin JL. Comparison of different fibers for in vitro
production of short-chain fatty acids by intestinal microflora. J Med Foods.
2005;8:113–6.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Niv et al. Nutrition & Metabolism  (2016) 13:10 Page 7 of 7
